| Course | PHLT 8270 Health Informatics and Surveillance |
|---|---|
| Week | Week 2 |
| Paper type | Discussion post |
| Length | About 520 words, 3 pages |
| Format | Discussion post, APA 7 citations |
| School | Walden University |
| Program | PhD in Public Health |
| Updated | October 2026 |
Free sample paper for PHLT 8270 Week 2
Week 2 Discussion: Initial Post and Replies
Resistant but Never Confirmed: How Requiring a Carbapenemase Test to Count a Case Shapes Which Patients a Composite State's Surveillance System Sees
Initial Post
In the composite state I am following, a carbapenem-resistant isolate does not become a confirmed case of carbapenemase-producing Enterobacterales until a test shows that the organism carries a carbapenemase gene or produces the enzyme. The rule makes sense. Resistance can arise in other ways, such as changes in the bacterial cell wall, and those organisms are far less likely to spread their resistance to other bacteria. Which isolates count as resistant in the first place also depends on the interpretive breakpoints a laboratory applies, which have been revised over the years (Humphries et al., 2019). A program that wants to find the organisms capable of fueling outbreaks needs to separate the two. My claim this week is that the confirmation rule also decides which patients the system can see, and not at random.
Confirmation depends on testing that happens after the clinical result. Some hospital laboratories run a phenotypic test for carbapenemase production themselves. Others send isolates to the state public health laboratory for molecular testing. Others, including many of the commercial laboratories that serve nursing homes, report resistance but neither test for mechanism nor ship isolates. Isolates from that last group remain "mechanism unknown," however dangerous they are.
That pattern falls hardest on the settings that matter most. Long-term care facilities and long-term acute care hospitals care for patients with long stays, devices and repeated antibiotic exposure, the patients among whom carbapenemase producers spread, and national surveillance has found most cases among older adults with health care exposure (Guh et al., 2015). If their specimens go to laboratories that do not confirm, the state's count of confirmed cases will understate exactly the settings where containment matters most. National containment work has relied on carbapenemase testing to trigger screening of contacts (Woodworth et al., 2018), so an unconfirmed isolate may also mean a response that never starts.
I am not arguing against the definition. Counting every resistant isolate as a carbapenemase producer would inflate the count with organisms that pose less risk and send investigators to the wrong places. I am arguing that the program should report confirmed cases alongside the number of isolates never tested for mechanism, by facility type, so readers can see where the definition leaves gaps.
For the group: in your system, who is most likely to meet the clinical criteria but never be confirmed?
Reply to Grace
Grace, your post on syphilis surveillance raised a similar issue: a reactive screening test becomes a case only after confirmatory testing and staging, and clinics without on-site follow-up lose patients between the two. Do you know whether your state reports the number of reactive screens never confirmed?
Reply to Luis
Luis, you argued that your state's foodborne illness definition, which requires a positive culture, undercounts cases because many laboratories now use culture-independent tests. That sounds like the same problem from the other direction: the testing method changed, and the definition did not. Has your state revised its definition to count culture-independent results as probable cases?
References
Guh, A. Y., Bulens, S. N., Mu, Y., Jacob, J. T., Reno, J., Scott, J., Wilson, L. E., Vaeth, E., Lynfield, R., Shaw, K. M., Vagnone, P. M. S., Bamberg, W. M., Janelle, S. J., Dumyati, G., Concannon, C., Beldavs, Z., Cunningham, M., Cassidy, P. M., Phipps, E. C., . . . Kallen, A. J. (2015). Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA, 314(14), 1479-1487. https://doi.org/10.1001/jama.2015.12480
Humphries, R. M., Abbott, A. N., & Hindler, J. A. (2019). Understanding and addressing CLSI breakpoint revisions: A primer for clinical laboratories. Journal of Clinical Microbiology, 57(6), e00203-19. https://doi.org/10.1128/JCM.00203-19
Woodworth, K. R., Walters, M. S., Weiner, L. M., Edwards, J., Brown, A. C., Huang, J. Y., Malik, S., Slayton, R. B., Paul, P., Capers, C., Kainer, M. A., Wilde, N., Shugart, A., Mahon, G., Kallen, A. J., Patel, J., McDonald, L. C., Srinivasan, A., Craig, M., & Cardo, D. M. (2018). Vital signs: Containment of novel multidrug-resistant organisms and resistance mechanisms, United States, 2006-2017. MMWR. Morbidity and Mortality Weekly Report, 67(13), 396-401. https://doi.org/10.15585/mmwr.mm6713e1
PHLT 8270 Week 2 instructions, in plain terms
Week 2's discussion typically asks students to examine the case definition of their chosen system and its effect on what the system counts. Faculty expect the definition to be stated accurately, its rationale acknowledged and its consequences analyzed, especially which groups are more likely to meet clinical criteria but never be confirmed. The post should explain whether those groups are random or systematic. Proposing a reporting change that makes the definition's gaps visible, without abandoning the definition, shows constructive judgment. Posts usually run about 500 words with sources on the condition and on surveillance methods. Replies should connect classmates' conditions to the same structural issue.
How the PHLT 8270 Week 2 example is put together
The post opens by stating the confirmation rule and its rationale, adding a note on how breakpoint revisions affect which isolates count as resistant. A paragraph explains how confirmation depends on whether laboratories test, refer or do neither. A paragraph explains why unconfirmed isolates concentrate in long-term care and long-term acute care hospitals, citing national surveillance and containment work that relies on mechanism testing to trigger screening. A paragraph argues for keeping the definition while reporting untested isolates by facility type, then asks classmates who in their systems goes unconfirmed. The reply to Grace connects syphilis confirmation to the same pattern. The reply to Luis notes that culture-independent tests challenge culture-based definitions.
Where the marks sit in the PHLT 8270 Week 2 rubric
Graders assess this post on accuracy, insight and constructiveness. Stating the case definition and its rationale correctly earns foundational credit. Insight comes from showing that the unconfirmed group is not random but concentrated in high-risk settings, which turns a technical rule into a question of whose risk the system sees. Constructiveness is shown by proposing a reporting change rather than attacking the definition. Accuracy is checked in claims about laboratory practices and the cited surveillance and containment findings. Replies earn credit when they identify the same structural problem in another condition. Clear writing, collegial tone and correct APA citations complete the criteria. The proposal to report untested isolates by facility type earns credit because it fixes a gap without discarding the definition.
PHLT 8270 Week 2 help from the desk
Case definition posts often either defend the definition uncritically or reject it for missing cases. The useful middle path accepts the definition's purpose and asks who it systematically leaves out. Trace confirmation back to the practices that produce it, such as which laboratories test. Ask whether missing cases cluster in particular settings or populations. Propose a way to make the gap visible, such as reporting unconfirmed cases separately. Use sources to support claims about where cases concentrate. In replies, look for definitions in classmates' systems that depend on a second test or a follow-up visit. Our writers will draft this post around your own system's definition as a free sample. Ask whose risk the definition makes invisible, then propose a way to show it.
Get a PHLT 8270 Week 2 example written to your instructions
Attach the Week 2 discussion prompt and rubric, and name the condition and case definition under debate in your thread. An initial post on who that definition holds back, with two replies, follows inside 24-48h, and the first one costs nothing. Its families and clinics are fictional; the gaps in your definition sit in its published criteria.
More PHLT 8270 papers and PhD in Public Health samples
- PHLT 8270 Week 1: Surveillance Coverage Post
- PHLT 8270 Week 3: Surveillance Data Flow Map
- PHLT 8270 Week 4: Surveillance System Evaluation
- PHLT 8270 Week 5: Data Quality Appraisal
- PHLT 8270 Week 6: Surveillance Trend Peer Critiques
- PHLT 8270 Week 7: Signal Interpretation Memo
- PHLT 8270 Week 8: Surveillance Data Governance Brief
- PHLT 8270 Week 9: Lab Interoperability Analysis
- PHLT 8270 Week 10: Outbreak Response Action Brief
- PHLT 8270 Week 11: Surveillance Synthesis Paper
- PHLT 8078 Week 2: Enforceable Limits Discussion Post
- PHLT 8076 Week 2: Reporting Unit Discussion Post
- PHLT 8074 Week 2: Exposure Methods Survey
- PHLT 8072 Week 2: Q Fever Chain of Infection Brief
PHLT 8270 Week 2 questions, answered
Where can I find a free PHLT 8270 Week 2 sample paper?
The complete Week 2 thread is published on this page, with an initial post on how a carbapenemase confirmation rule shapes which patients a surveillance system sees and two replies. The cited studies are real.
Where do surveillance case definitions come from?
In the United States, many are developed by the Council of State and Territorial Epidemiologists with federal partners and adopted by states, sometimes with changes. States may also define conditions of local concern. Definitions set the clinical and laboratory criteria a report must meet to count.
Is it fair to criticize a definition built to prevent false cases?
Yes, if the criticism is about consequences rather than purpose. The sample accepts that requiring a mechanism test separates the organisms that spread resistance, then shows how the rule makes cases in certain settings less likely to be confirmed.
Who is most likely to go unconfirmed under a mechanism test rule?
Patients whose specimens go to laboratories that neither test for carbapenemase nor send isolates to the state, often nursing home residents served by commercial laboratories. That pattern concentrates unconfirmed cases where containment matters most.
Should the definition be changed to count every resistant isolate?
The sample argues no, because that would mix in organisms that pose less risk. It recommends keeping the definition and reporting the number of resistant isolates never tested for mechanism, by facility type, so the gap is visible.